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Merkel cell carcinoma incidence, trends, and survival rates 
among adults aged ≥50 years from United States Cancer 
Statistics
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Lunsford, PhDb
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To the Editor: Merkel cell carcinoma (MCC) is a rare form of skin cancer that frequently 
metastasizes and is associated with low survival rates.1 A recent examination of data from 
the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) 
program—specifically SEER-18 data, which captures 28% of the US population—revealed 
an increase in MCC incidence rates during 2000–2013.2 For the current study, we used data 
from the United States Cancer Statistics, which combines state cancer registry data from the 
Centers for Disease Control and Prevention’s National Program of Cancer Registries and the 
SEER program (https://www.cdc.gov/cancer/uscs/about/index.htm), to examine patterns in 
MCC incidence and survival by sex, age, race/ethnicity, tumor stage, and anatomic site.
We analyzed data from the United States Cancer Statistics Public Use Database, which 
covered 100.0% of the US population during 2006–2015.3 Survival data were only available 
from 39 states participating in the National Program of Cancer Registries data set and 
covered 81.1% of the US population during 2005–2014, the most recent years for which 
survival data is available. Analyses were limited to cases ≥50 years because few cases are 
diagnosed before the age of 50 years (438 cases or 2%), limiting statistical reliability of 
analyses. We calculated MCC incidence rates per 100,000 persons and annual percent 
change for the years 2006–2015, age-adjusted to the 2000 US population standard. Five-year 
relative survival rates for the years 2005–2014 were calculated using the actuarial method.
During 2006–2015, there were an average of 1972 MCC cases/year (19,722 cases total) 
(Table I). MCC incidence rates increased with increasing age among men and women and 
were higher among non-Hispanic whites (2.5/100,000 persons), localized stage (1.2/100,000 
persons), and tumors located on the head and neck (0.9/100,000 persons). The annual 
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percent change in incidence rates was highest among 70–74-year-olds (4.1%), non-Hispanic 
whites (2.7%), distant stage tumors (5.0%), and tumors of the upper extremities (2.6%). 
Five-year relative survival rate was 55.1% among men and 67.7% among women (Table II). 
Survival rates decreased with later stage and older age at diagnosis and were lowest among 
non-Hispanic blacks (54.1%) and tumors of the trunk (49.0%).
Consistent with the findings by Paulson et al,2 these results indicate an increase in MCC 
incidence rates during 2006–2015 overall, particularly among men>70 years of age, women 
aged 65–74 years, and non-Hispanic whites. The 5-year relative survival rates for MCC 
ranged from 35.2% among men ≥85 years of age to 82.9% among women 60–64 years of 
age and was lower for localized stage (72.5%) than malignant melanoma (83.6%−94.1% 
among age groups and 97.1% for localized stage).3
Using cancer registry data that cover the entire US population, we observed an increasing 
trend of MCC incidence rates across all stages during 2006–2015. The observed increasing 
trends among older adults might be related to changes in known MCC risk factors over time 
at a population level.4 Such factors include ultraviolet exposure and a weakened immune 
system.4 Further research into other causes, prevention, and treatment of MCC is warranted 
to address the increasing trends and lower survival rates in this type of cancer.
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